
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna projects significant growth in product sales, with expectations of $1.73 billion in 2025 rising to $2.15 billion in 2026, underscoring increasing market demand for its mRNA products. The company's recent $1.5 billion debt deal enhances its balance sheet and provides flexibility to navigate uncertainties while pursuing future opportunities. Additionally, improvements in manufacturing efficiency are anticipated to expand gross margins, which have rebounded from 30% in 2023 to 50% in 2025, projecting a positive financial trajectory as the company aims for cash break-even by 2028.
Bears say
Moderna's financial outlook is hindered by a significant decline in COVID vaccine sales, which dropped from $18 billion in 2022 to $6.7 billion in 2023, alongside reduced guidance for 2025 stemming from anticipated lower vaccination rates as the pandemic transitions to endemic status. The firm's revised projections indicate a decrease in long-term COVID revenue expectations from $3.5 billion to $2.5 billion annually, compounded by poor negotiations in the European market, leading to low sales expectations for 2024 and potentially 2025. Furthermore, overall enterprise value has been adjusted from $22.12 billion to $21.53 billion, reflecting ongoing challenges and headwinds in both their RSV and COVID programs.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares